In his 30-year industry career, Dr. Springman has led the development of new medicines in cancer, inflammation, fibrosis, and osteoporosis, from preclinical development to Phase 3 clinical trials.

His expertise spans across preclinical and clinical development, manufacturing and regulatory affairs. Most recently, he was CSO at Celtaxsys Inc, where he led the development of acebilustat (CTX-4430), a first-in-class immune modulator still in development. Before Celtaxsys, Dr. Springman was at Roche and Locus Pharma, leading development of new therapies in cancer, fibrosis, and respiratory diseases.

He earned his PhD in molecular biophysics from Florida State University and did postdoctoral training in clinical pharmacology and immunology at Vanderbilt University.